Identification of IMPDH2 as a tumor-associated antigen in colorectal cancer using immunoproteomics analysis

International Journal of Colorectal Disease

Volumn 24, Issue 11, 2009, Pages 1271-1279

  He, Yujun ^a,b   Mou, Zhirong ^b   Li, Wanlin ^b   Liu, Baohua ^a   Fu, Tao ^a   Zhao, Shong ^a   Xiang, Debing ^a   Wu, Yuzhang ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Immunoproteomics analysis; Inosine monophosphate dehydrogenase II (IMPDH2); Tumor associated antigens

Indexed keywords

AUTOANTIBODY; HEAT SHOCK PROTEIN 60; INOSINATE DEHYDROGENASE; INOSINE MONOPHOSPHATE DEHYDROGENASE 2; PROTEIN ANTIBODY; TUMOR ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ANTIGEN EXPRESSION; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER TISSUE; CELL STRAIN HCT116; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; AUTOANTIBODIES; BLOTTING, WESTERN; COLORECTAL NEOPLASMS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HCT116 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IMP DEHYDROGENASE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROTEOMICS; ROSANILINE DYES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 70350007904     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-009-0759-2     Document Type: Article

References (39)

1. Hanash S (2003) Disease proteomics. Nature 422:226-232
2. Imafuku Y, Omenn GS, Hanash S (2004) Proteomics approaches to identify tumor antigen directed autoantibodies as cancer biomarkers. Dis Markers 20:149-153
3. Seliger B, Kellner R (2002) Design of proteome-based studies in combination with serology for the identification of biomarkers and novel targets. Proteomics 2:1641-1651
4. Omenn GS (2006) Strategies for plasma proteomic profiling of cancers. Proteomics 6:5662-5673
5. Guo Y, Fu Z, Van Eyk JE (2007) A proteomic primer for the clinician. Proc Am Thorac Soc 4:9-17
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96
7. Sung JJ, Lau JY, Young GP, Sano Y, Chiu HM, Byeon JS, Yeoh KG, Goh KL, Sollano J, Rerknimitr R, Matsuda T, Wu KC, Ng S, Leung SY, Makharia G, Chong VH, Ho KY, Brooks D, Lieberman DA, Chan FK (2008) Asia Pacific consensus recommendations for colorectal cancer screening. Gut 57:1166-1176
8. Bielicki D, Karbowniczek M, Sulzyc-Bielicka V, Kladny J, Boer C, Marlicz K, Domagala W (1999) Clinico-pathological characteristics of colorectal cancer and serum anti-p53 antibodies. Pol J Pathol 50:77-81
9. Mosolits S, Harmenberg U, Ruden U, Ohman L, Nilsson B, Wahren B, Fagerberg J, Mellstedt H (1999) Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma. Cancer Immunol Immunother 47:315-320
10. Albanopoulos K, Armakolas A, Konstadoulakis MM, Leandros E, Tsiobanou E, Katsaragakis S, Alexiou D, Androulakis G (2000) Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer. Am J Gastroenterol 95:1056-1061
11. Gerhardt A, Usener D, Keese M, Sturm J, Schadendorf D, Eichmuller S (2004) Tissue expression and sero-reactivity of tumor-specific antigens in colorectal cancer. Cancer Lett 208:197-206
12. Rosenfeld J, Capdevielle J, Guillemot JC, Ferrara P (1992) In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis. Anal Biochem 203:173-179
13. Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L (1994) CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369:67-71
14. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716-719
15. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265-270
16. Unwin RD, Harnden P, Pappin D, Rahman D, Whelan P, Craven RA, Selby PJ, Banks RE (2003) Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 3:45-55
17. Klade CS, Voss T, Krystek E, Ahorn H, Zatloukal K, Pummer K, Adolf GR (2001) Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 1:890-898
18. Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, Hanash SM (2001) An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 98:9824-9829
19. Brichory F, Beer D, Le Naour F, Giordano T, Hanash S (2001) Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 61:7908-7912
20. Hong SH, Misek DE, Wang H, Puravs E, Giordano TJ, Greenson JK, Brenner DE, Simeone DM, Logsdon CD, Hanash SM (2004) An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 64:5504-5510
21. Le Naour F, Misek DE, Krause MC, Deneux L, Giordano TJ, Scholl S, Hanash SM (2001) Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 7:3328-3335
22. Le Naour F, Brichory F, Misek DE, Brechot C, Hanash SM, Beretta L (2002) A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics 1:197-203
23. Lichtenfels R, Kellner R, Atkins D, Bukur J, Ackermann A, Beck J, Brenner W, Melchior S, Seliger B (2003) Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim Biophys Acta 1646:21-31
24. Rauch J, Ahlemann M, Schaffrik M, Mack B, Ertongur S, Andratschke M, Zeidler R, Lang S, Gires O (2004) Allogenic antibody-mediated identification of head and neck cancer antigens. Biochem Biophys Res Commun 323:156-162
25. Fujita Y, Nakanishi T, Hiramatsu M, Mabuchi H, Miyamoto Y, Miyamoto A, Shimizu A, Tanigawa N (2006) Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 12:6415-6420
26. Fujita Y, Nakanishi T, Miyamoto Y, Hiramatsu M, Mabuchi H, Miyamoto A, Shimizu A, Takubo T, Tanigawa N (2008) Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett 263:280-290
27. Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, Welch WR, Bandera CA, Mok SC (2008) Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res 14:764-771
28. Senda M, Natsumeda Y (1994) Tissue-differential expression of two distinct genes for human IMP dehydrogenase (E.C.1.1.1.205). Life Sci 54:1917-1926
29. Jackson RC, Weber G, Morris HP (1975) IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 256:331-333
30. Itoh O, Kuroiwa S, Atsumi S, Umezawa K, Takeuchi T, Hori M (1989) Induction by the guanosine analogue oxanosine of reversion toward the normal phenotype of K-ras-transformed rat kidney cells. Cancer Res 49:996-1000
31. Collart FR, Chubb CB, Mirkin BL, Huberman E (1992) Increased inosine-5′-phosphate dehydrogenase gene expression in solid tumor tissues and tumor cell lines. Cancer Res 52:5826-5828
32. Brouwer C, Vermunt-de Koning DG, Trueworthy RC, Ter Riet PG, Duley JA, Trijbels FJ, Hoogerbrugge PM, Bokkerink JP, van Wering ER, De Abreu RA (2006) Monitoring of inosine monophosphate dehydrogenase activity in mononuclear cells of children with acute lymphoblastic leukemia: enzymological and clinical aspects. Pediatr Blood Cancer 46:434-438
33. Hager PW, Collart FR, Huberman E, Mitchell BS (1995) Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol 49:1323-1329
34. Zimmermann A, Gu JJ, Spychala J, Mitchell BS (1996) Inosine monophosphate dehydrogenase expression: Transcriptional regulation of the type I and type II genes. Adv Enzyme Regul 36:75-84
35. Floryk D, Thompson TC (2008) Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells. Int J Cancer 123:2294-2302
36. Yalowitz JA, Jayaram HN (2000) Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis. Anticancer Res 20:2329-2338
37. Khanna N, Jayaram HN, Singh N (2004) Benzamide riboside induced mitochondrial mediated apoptosis in human lung cancer H520 cells. Life Sci 75:179-190
38. Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Podar K, Le Gouill S, Shiraishi N, Yasui H, Roccaro AM, Tai YZ, Chauhan D, Fram R, Tamura K, Jain J, Anderson KC (2005) Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene 24:5888-5896
39. Chen L, Pankiewicz KW (2007) Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. Curr Opin Drug Discov Devel 10:403-412